Skip to main content

Table 1 Serum levels of sCD40L, CA19-9, and CEA in both training and independent validation datasets

From: Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma

(Training set)

Groups (n)

Values

Normal (n = 25)

CP†(n = 25)

PDAC (n = 25)

p- value‡

Serum sCD40L (ng/ml)

9170.5 ± 5449.8*

17648.9 ± 7264.0

30044.2 ± 9747.9

< 0.001

Serum CA19-9 (U/ml)

7.9 ± 7.1

136.8 ± 329.8

5795.4 ± 7842.7

< 0.001

Serum CEA (ng/ml)

2.3 ± 1.5

2.9 ± 2.0

367.9 ± 1709.4

0.428

(Validation set)

Groups (n)

Values

Normal (n = 30)

CP (n = 30)

PDAC (n = 55)

p- value ‡

Serum sCD40L (ng/ml)

10540.1 ± 5159.9

18709.4 ± 8786.6

27924.6 ± 10202.9

< 0.001

Serum CA19-9 (U/ml)

8.5 ± 7.5

119.6 ± 299.7

3932.7 ± 6839.2

< 0.001

Serum CEA (ng/ml)

2.2 ± 1.4

2.6 ± 2.0

271.4 ± 1246.8

0.359

  1. sCD40L, soluble CD40 ligand; CA19-9, carbohydrate antigen 19–9; CEA, carcinoembryonic antigen; CP, chronic pancreatitis; PDAC, pancreatic ductal adenocarcinoma.
  2. *All tested values are expressed as the mean ± standard deviation.
  3. †We included CP patients as the high-risk group of PDAC.
  4. ‡One-way ANOVA test with the multiple comparisons using the post-hoc Bonferroni method is applied to compare the differences in the means among three disease groups.
  5. p < 0.05 (two-tailed) was considered to be statistically significant.
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us